Elvitegravir
As of the edition of 20 October 2026, Elvitegravir is a small molecule: marketed, first approved in 2012 (US); US protection ends in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Small molecule
- Brand name
- Stribild
- First approved
- 27 August 2012 (US)
- Approvals on record
- 11 in 4 regions
- Holder of the most recent approval
- Japan Tobacco; 4 holders in all
- Withdrawn from market
- 3 November 2016 (in some regions)
- Registered trials
- 33, 2 stopped early
- Disease areas
- Immune system; Infections; Urinary and reproductive; Bones, joints and muscles; Mental health; Nutrition and metabolism
US protection
US protection ends in 2026.
The last listed US drug-substance patent ends in 2026. The application that gives this date is held by Gilead Sciences.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product6 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 6 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 3 | 0 | 0 |
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 4 | 4 | 0 | 0 |
| Phase 3 | 8 | 7 | 0 | 1 |
| Phase 4 | 10 | 7 | 0 | 1 |
| All trials | 33 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Applicant and Lead sponsor of trials | 2006 to now |
| Japan Tobacco | Applicant | 2013 to now |